Pharmacological treatment options include statins as a first-line therapy, with ezetimibe and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors as add-on therapy options in case of persistent dyslipidemia. Here, PCSK9 is linked to metabolic syndrome.